Clinical Research
News & Careers
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile



Corporate Headquarters
One Amgen Center Drive
Thousand Oaks  California  91320-1789  U.S.A.
Phone: 805-447-1000 Fax: 805-447-1010


About Amgen

Amgen, a pioneer in biotechnology, harnesses the power of cellular and molecular biology and medicinal chemistry to discover, develop and deliver innovative human therapeutics. For more than 25 years, Amgen science has generated important medical discoveries, resulting in medicines that have helped millions of patients fight cancer, kidney disease, rheumatoid arthritis, and other serious illnesses.

Scientific innovation is our heritage and our future. With a deep and broad pipeline of potential new therapeutic candidates, and active research programs in oncology, inflammation, metabolic and bone disorders, hematology, nephrology, and neuroscience, we are dedicated to advancing science to help patients. That dedication shows in our interdisciplinary and modality-independent approach to research and development. Amgen scientists first identify a disease target and then select the best modality – protein, small molecule, or antibody – to interact with that target to block the disease process.

To fully realize the promise of biotechnology to dramatically improve people’s lives, we extend science beyond the lab and clinic, into the production plant. Amgen is recognized worldwide for unparalleled expertise in the complex field of biologics manufacturing. We currently produce more than a third of the world’s non-vaccine and non-insulin protein therapeutics, and we adhere to the highest standards of quality and consistency to ensure a reliable supply of vital medicines for the many patients who need them.

Headquartered in Southern California, with offices or subsidiaries in 31 countries, Amgen is traded on the NASDAQ stock exchange under the symbol AMGN. Amgen is committed to our mission to serve patients – a mission that unites our 15,000 staff members around the world. For more information about Amgen, our pioneering science, and our vital medicines, visit

 Key Statistics

Ownership: Public

Web Site: Amgen
Employees: 7,300+ Worldwide
Symbol: AMGN


Genesis Research and Development Corporation 

Phylos, Inc.  In 2000, Phylos entered into collaboration with Amgen to apply Phylos' PROfusion™ technology to rapidly identify high-affinity binding agents to potential therapeutic targets supplied by Amgen. Amgen will use the sequences and structural information gained through this collaboration for its internal drug discovery programs.

UCB, Inc.  Contract manufacturing of Abarelix peptide active ingredient

EPIX Pharmaceuticals, Inc. 

Dyax Corp.  Antibody phage display

 Company News
Amgen (AMGN) Announces Webcast Of 2015 First Quarter Financial Results 4/17/2015 6:44:14 AM
BayBio Institute Names Amgen (AMGN) Bay Area Winners 4/16/2015 9:37:05 AM
Amgen (AMGN) Release: FDA Approves Corlanor (ivabradine) To Reduce The Risk Of Hospitalization For Worsening Heart Failure In Patients With Chronic Heart Failure 4/16/2015 6:03:13 AM
Analysts Cheer As Amgen (AMGN) Nabs Long-Awaited FDA Approval of Heart Failure Drug Corlanor 4/16/2015 6:02:24 AM
Amgen (AMGN) CEO Gets $14M Payday, But Colleagues Who Took Pay Cuts May Disagree 4/6/2015 11:10:39 AM
Gilead (GILD) and Amgen (AMGN) Hand Out Dividends; Other Biotechs Feel the Heat So Who's Next? 4/6/2015 6:37:56 AM
European Commission (EC) Approves Amgen (AMGN)'s Vectibix (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Metastatic Colorectal Cancer 4/6/2015 6:34:05 AM
Amgen (AMGN) in the Crosshairs As Biogen (BIIB), Hospira, Merck & Co. (MRK) All Climb on Biosimilar Bandwagon: Citi 3/31/2015 4:06:05 PM
Amgen (AMGN) To Present At The Goldman Sachs Key Debates In Biosimilars Conference 3/30/2015 3:53:26 PM
FDA Grants Amgen (AMGN) Priority Review For Kyprolis (Carfilzomib) Supplemental New Drug Application For The Treatment Of Relapsed Multiple Myeloma 3/30/2015 12:16:29 PM